To better your understanding of non-clinical career options and/or facilitate your physician career change, today we introduce you to Jospeh Amprey, MD, PhD. Dr.Amprey is a member of the Metastatix Board of Directors and is also a Principal at MedImmune Ventures.
Metastatix, Inc. is a privately held pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing effective, convenient, and safe small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Metastatix is committed to developing drugs that are effective, convenient to take, and have few side effects. Metastatix has pioneered the development of a series of novel oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.
Dr. Amprey joined MedImmune Ventures, Inc. in 2006 as a principal focused on deal sourcing and portfolio management. MedImmune Ventures, Inc. is a wholly owned venture capital subsidiary of MedImmune, Inc. It was created in 2002 to leverage the company’s expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies. MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies focused on discovering and developing human therapeutics. MedImmune Ventures primarily seeks to invest in areas of strategic interest to MedImmune, including infectious diseases, cancer and inflammatory diseases.
Prior to joining MedImmune Ventures, Dr. Amprey was responsible for deal sourcing and held operational roles within the Carrot Capital (CCHV) portfolio companies.
Previously, he completed an internship in internal medicine at both New York-Presbyterian Hospital and Memorial Sloan-Kettering. During medical school, he was an independent consultant to Arch Venture Partners. Dr. Amprey currently serves as a director of Synovex Corporation, Inc. and is an observer on the boards of Elusys Therapeutics, Inc. and VLST Corporation.
Dr. Amprey earned both his doctorate in immunology and his medical degree from Cornell University Weill Medical College. He holds a bachelor’s degree in biochemistry from the University of Pennsylvania. He also received postgraduate training at the Brigham and Womens’ Hospital and Albert Einstein College of Medicine.
For more information about Dr. Amprey and these two companies, please visit the Metastatix and Medimmune Ventures websites.
